NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
0 hedge funds and large institutions have $0 invested in NKGen Biotech, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $161K → $0 (-$161K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$93.3K |
| 2 |
UOC
University of Chicago
Chicago,
Illinois
|
-$58.5K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
-$9K |
NKGN Hedge Fund Activity: Q2 2025 in Review
0 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q2 2025, worth a combined $0 — down 100% from $161K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NKGN and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Diametric Capital, exiting entirely with an estimated $93.3K sold.
- 0 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q2 2025, down from 3 in Q1 2025.
- Funds reported $0 of NKGen Biotech, Inc. Common Stock stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new NKGen Biotech, Inc. Common Stock positions in Q2 2025 and 3 closed out, a net change of -3 holders.
- The largest NKGen Biotech, Inc. Common Stock seller in Q2 2025 was Diametric Capital, an estimated $93.3K sold.
Based on aggregated 13F filings for Q2 2025.